Management of Intraductal Papillary Mucinous Neoplasms: Controversies in Guidelines and Future Perspectives

• Published in: Current treatment options in gastroenterology 2018-09, Vol.16 (3), p.316-332
• Main Authors: Levink, IJM, Bruno, MJ, Cahen, DL
• Format: Article
• Language: English
• Subjects: Endoscopy (P Siersema; Endoscopy (P Siersema, Section Editor); Gastroenterology; Medicine; Medicine & Public Health; Section Editor; Topical Collection on Endoscopy
• ISSN: 1092-8472; 1534-309X
• DOI: 10.1007/s11938-018-0190-2

Purpose of review Management of intraductal papillary mucinous neoplasm (IPMN) is currently based on consensus, in the absence of evidence-based guidelines. In recent years, several consensus guidelines have been published, with distinct management strategies. In this review, we will discuss these discrepancies, in order to guide treating physicians in clinical management. Recent findings The detection rate of pancreatic cysts has increased substantially with the expanded use of high-quality imaging techniques to up to 45%. Of these cysts, 24–82% are IPMNs, which harbour a malignant potential. Timely detection of high-risk lesions is therefore of great importance. Surgical management is based on the presence of clinical and morphological high-risk features, yet the majority of resected specimens appear to be low risk. Summary International collaboration and incentive large-scale prospective registries of individuals undergoing cyst surveillance are needed to accumulate unbiased data and develop evidence-based guidelines. Additionally, development of non-invasive, accurate diagnostic tools (e.g. biomarkers) is needed to differentiate between neoplastic and non-neoplastic pancreatic cysts and detect malignant transformation at an early stage (i.e. high-grade dysplasia).